Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

by Chng, WJ, Huang, GF, Chung, TH, Ng, SB, Gonzalez-Paz, N, Troska-Price, T, Mulligan, G, Chesi, M, Bergsagel, PL, Fonseca, R
Published 2011

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma

by Matthews, G M, Lefebure, M, Doyle, M A, Shortt, J, Ellul, J, Chesi, M, Banks, K-M, Vidacs, E, Faulkner, D, Atadja, P, Bergsagel, P L, Johnstone, R W
Published 2013